Tanzisertib HCl(CC-930)

製品コードS8490 バッチS849001

印刷

化学情報

Synonyms

JNK-930, JNKI-1

Storage
(From the date of receipt)

3 years -20°C powder
1 years -80°C in solvent

化学式

C₂₁H₂₃F₃N₆O₂.HCl

分子量

484.9

CAS No.

2517855-91-1

Solubility (25°C)*

体外

DMSO (warmed with 50ºC water bath)

89 mg/mL (183.54 mM)

Ethanol (warmed with 50ºC water bath)

89 mg/mL (183.54 mM)

Water (warmed with 50ºC water bath)

4 mg/mL (8.24 mM)

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	4.400mg/ml (9.07mM)	Taking the 1 mL working solution as an example, add 50 μL of 88 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	0.550mg/ml (1.13mM)	Taking the 1 mL working solution as an example, add 50 μL of 11 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Tanzisertib HCl(CC-930, JNK-930, JNKI-1) is kinetically competitive with ATP in the JNK-dependent phosphorylation of the protein substrate c-Jun and potent against all isoforms of JNK (Ki(JNK1) = 44 ± 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ± 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM) and selective against MAP kinases ERK1 and p38a with IC50 of 0.48 and 3.4 μM respectively.
in vitro	Tanzisertib HCl (CC-930) inhibits the formation of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemeagglutinin (IC50 = 1 μM). It shows remarkable selectivity in a panel of 240 kinases, EGFR being the only non-MAP kinase inhibited more than 50% at 3 μM (IC50 = 0.38 μM). This compound inhibits no receptor at greater than 50% at 10 μM concentration in a panel of 75 receptors, ion channels and neurotransmitter transporters. It does not inhibit CYP P450 enzymes significantly and is metabolized by CYP 3A4 and 2D6^[1].
in vivo	In the acute rat LPS-induced TNFα production PK-PD model, Tanzisertib HCl (CC-930) inhibits the production of TNFα by 23% and 77% at 10 and 30 mg/kg oral dose respectively. It is well-tolerated and exposure is dose-proportional^[1].

プロトコル(参考用のみ)

細胞アッセイ	細胞株	Jurkat T cells
	濃度	--
	反応時間	30 minutes
	実験の流れ	Jurkat T cells (5×10⁵ /well) are aliquoted in 96 well membrane filter plates, then treated with or without Tanzisertib HCl (CC-930) 30 minutes prior to stimulation with 0.3 μg/ml anisomycin for an additional 40 minutes. Cells are pelleted under vacuum with plate manifold. Cell lysates are prepared by adding 75 μl/well lysis buffer (20 mM HEPES pH 7.4, 100 mM NaCl, 0.2% Triton X-100, 0.5 mM DTT, 2x phosphatase inhibitors, 20 mM PNPP, 1x protease inhibitors), for 30 minutes at room temperature. Lysates are filtered and collected into a new 96 well plate placed beneath the vacuum manifold. Cell lysates (45 μl) are added to an assay plate containing bound GST-c-Jun and MgCl2 in solution (10 mM) then incubated for 10 minutes at room temperature. The reaction is stopped by washing with Tris-buffered saline containing 0.02% Tween 20 and the phosphorylated GST-c-Jun detected by Europium labeled anti-phospho-c-Jun, DELFIA assay buffer and enhancement solution. Plate fluorescence is measured.
動物実験	動物モデル	Male C57Bl/6 mice
	投薬量	2 mg/kg(i.v.) or 10 mg/kg(p.o.)
	投与方法	i.v. or p.o.

参考

https://pubmed.ncbi.nlm.nih.gov/22244937/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Pathology-oriented multiplexing enables integrative disease mapping [ Nature, 2025, 644(8076):516-526]	PubMed: 40681898
CD22 modulation alleviates amyloid β-induced neuroinflammation [ J Neuroinflammation, 2025, 22(1):32]	PubMed: 39910617
Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer [ Cancer Cell, 2024, 42(4):535-551.e8]	PubMed: 38593780
Short-term tamoxifen administration improves hepatic steatosis and glucose intolerance through JNK/MAPK in mice [ Signal Transduct Target Ther, 2023, 8(1):94]	PubMed: 36864030
A Chemical Proteomics Approach to Discover Regulators of Innate Immune Signaling [ Viruses, 2023, 15(5)1112]	PubMed: 37243198
Alternative splicing of apoptosis genes promotes human T cell survival [ Elife, 2022, 11e80953]	PubMed: 36264057
The Global Phosphorylation Landscape of SARS-CoV-2 Infection [ Cell, 2020, 182(3):685-712.e19]	PubMed: 32645325
The Global Phosphorylation Landscape of SARS-CoV-2 Infection [ Cell, 2020, 182(3):685-712.e19]	PubMed: 32645325
PLEK2 mediates metastasis and vascular invasion via the ubiquitin-dependent degradation of SHIP2 in non-small cell lung cancer. [ Int J Cancer, 2020, 146(9):2563-2575]	PubMed: 31498891
Targeting JNK pathway promotes human hematopoietic stem cell expansion. [ Cell Discov, 2019, 5:2]	PubMed: 30622738

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。